Skip to main content

Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma.

Publication ,  Journal Article
Stevenson, M; Mostertz, W; Acharya, C; Kim, W; Walters, K; Barry, W; Higgins, K; Tuchman, SA; Crawford, J; Vlahovic, G; Ready, N; Onaitis, M; Potti, A
Published in: Clin Cancer Res
December 15, 2009

PURPOSE: Cancer cells possess traits reminiscent of those ascribed to normal stem cells. It is unclear whether these phenotypic similarities are the result of a common biological phenotype, such as regulatory pathways. EXPERIMENTAL DESIGN: Lung cancer cell lines with corresponding gene expression data and genes associated with an embryonic stem cell identity were used to develop a signature of embryonic stemness (ES) activity specific to lung adenocarcinoma. Biological characteristics were elucidated as a function of cancer biology/oncogenic pathway dysregulation. The ES signature was applied to three independent early-stage (I-IIIa) lung adenocarcinoma data sets with clinically annotated gene expression data. The relationship between the ES phenotype and cisplatin (current standard of care) sensitivity was evaluated. RESULTS: Pathway analysis identified specific regulatory networks [Ras (P = 0.0005), Myc (P = 0.0224), wound healing (P < 0.0001), chromosomal instability (P < 0.0001), and invasiveness (P < 0.0001)] associated with the ES phenotype. The prognostic relevance of the ES signature, as related to patient survival, was characterized in three cohorts [CALGB 9761 (n = 82; P = 0.0001), National Cancer Institute Director's Challenge Consortium (n = 442; P = 0.0002), and Duke (n = 45; P = 0.06)]. The ES signature was not prognostic in prostate, breast, or ovarian adenocarcinomas. Lung tumors (n = 569) and adenocarcinoma cell lines (n = 31) expressing the ES phenotype were more likely to be resistant to cisplatin (P < 0.0001 and P = 0.006, respectively). CONCLUSIONS: Lung adenocarcinomas that share a common gene expression pattern with normal human embryonic stem cells were associated with decreased survival, increased biological complexity, and increased likelihood of resistance to cisplatin. This indicates the aggressiveness of these tumors.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Cancer Res

DOI

EISSN

1557-3265

Publication Date

December 15, 2009

Volume

15

Issue

24

Start / End Page

7553 / 7561

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Stevenson, M., Mostertz, W., Acharya, C., Kim, W., Walters, K., Barry, W., … Potti, A. (2009). Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma. Clin Cancer Res, 15(24), 7553–7561. https://doi.org/10.1158/1078-0432.CCR-09-1939
Stevenson, Marvaretta, William Mostertz, Chaitanya Acharya, William Kim, Kelli Walters, William Barry, Kristin Higgins, et al. “Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma.Clin Cancer Res 15, no. 24 (December 15, 2009): 7553–61. https://doi.org/10.1158/1078-0432.CCR-09-1939.
Stevenson M, Mostertz W, Acharya C, Kim W, Walters K, Barry W, et al. Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma. Clin Cancer Res. 2009 Dec 15;15(24):7553–61.
Stevenson, Marvaretta, et al. “Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma.Clin Cancer Res, vol. 15, no. 24, Dec. 2009, pp. 7553–61. Pubmed, doi:10.1158/1078-0432.CCR-09-1939.
Stevenson M, Mostertz W, Acharya C, Kim W, Walters K, Barry W, Higgins K, Tuchman SA, Crawford J, Vlahovic G, Ready N, Onaitis M, Potti A. Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma. Clin Cancer Res. 2009 Dec 15;15(24):7553–7561.

Published In

Clin Cancer Res

DOI

EISSN

1557-3265

Publication Date

December 15, 2009

Volume

15

Issue

24

Start / End Page

7553 / 7561

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis